Experimental HIV Drugs
Experimental HIV Drugs
CROI 2016: Combination Inhibitor BMS-986197 Demonstrates Good Anti-HIV Activity in Early Study
- Details
- Category: Experimental HIV Drugs
- Published on Monday, 14 March 2016 00:00
- Written by Liz Highleyman
A long-acting bioengineered "combinectin" molecule with a triple mechanism of action demonstrated potent antiviral activity and worked against HIV that developed resistance to any of the 3 separate mechanisms in a laboratory study, and lowered viral load in humanized mice, according to research presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston.
FDA Approves Second TAF-Containing Single-Tablet HIV Regimen
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 04 March 2016 00:00
- Written by Gilead Sciences
The U.S. Food and Drug Administration (FDA) this week approved Gilead Sciences' new once-daily single-tablet regimen Odefsey, containing the NNRTI rilpivirine (developed by Janssen), emtricitabine, and tenofovir alafenamide or TAF, a new formulation that is easier on the kidneys and bones than the older tenofovir disoproxil fumarate or TDF.
CROI 2016: Long-Acting Injectable Cabotegravir + Rilpivirine Works Well as HIV Maintenance Therapy
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 23 February 2016 00:00
- Written by Liz Highleyman
A combination of 2 long-acting injectable antiretrovirals, cabotegravir and rilpivirine, given once every 4 or 8 weeks, maintained viral suppression as well as standard oral antiretroviral therapy (ART) and appeared safe and well-tolerated, according to results from the LATTE 2 trial presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) taking place this week in Boston.
CROI 2016: TAF/FTC Maintains Viral Suppression as Well as TDF with Less Bone and Kidney Toxicity
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 24 February 2016 00:00
- Written by Liz Highleyman
A fixed-dose coformulation of tenofovir alafenamide (TAF) and emtricitabine (FTC), combined with a variety of third antiretroviral agents, maintained undetectable viral load in people who switched from similar regimens containing the older tenofovir disoproxil fumarate (TDF), according to a report presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)this week in Boston. The study also showed improvement in kidney function biomarkers and bone density gains in the group taking TAF/FTC.
ViiV and Janssen To Collaborate on Long-Acting Injectable HIV Treatment
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 20 January 2016 00:00
- Written by ViiV Healthcare
ViiV Healthcare and Janssen have announced a plan to work together on the development of long-acting injectable HIV treatment using ViiV's investigational integrase inhibitor cabotegravir and an injected formulation of Janssen's currently available oral NNRTI rilpivirine (Edurant).
More Articles...
- FDA Approves Gilead's Genvoya Single-tablet Regimen with Tenofovir Alafenamide
- Long-acting Injectable Cabotegravir + Rilpivirine Maintains HIV Suppression for 32 Weeks
- EACS 2015: HIV Maturation Inhibitor BMS-955176 Shows Good Safety and Efficacy in Phase 2a Trial
- EACS 2015: TAF Single-Tablet Regimen Shows Good Efficacy, Improved Kidney and Bone Safety
Web Design and Development by